Invex Therapeutics Ltd. (AU:IXC)
ASX:IXC
Total Valuation
Invex Therapeutics Ltd. has a market cap or net worth of AU$6.91M. The enterprise value is AU$2.32M.
Market CapAU$6.91M
Enterprise ValueAU$2.32M
Share Statistics
Invex Therapeutics Ltd. has 75,153,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding75,153,850
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Invex Therapeutics Ltd.’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is -13.52%.
Return on Equity (ROE)-0.09
Return on Assets (ROA)-0.09
Return on Invested Capital (ROIC)-13.52%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee57.27K
Profits Per Employee-119.22K
Employee Count4
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Invex Therapeutics Ltd. is ―. Invex Therapeutics Ltd.’s PEG ratio is 0.20.
PE Ratio―
PS Ratio29.41
PB Ratio1.28
Price to Fair Value1.28
Price to FCF-10.32
Price to Operating Cash Flow-10.60
PEG Ratio0.20
Income Statement
In the last 12 months, Invex Therapeutics Ltd. had revenue of 229.08K and earned -476.87K in profits. Earnings per share was -0.01.
Revenue229.08K
Gross Profit229.08K
Operating Income-709.30K
Pretax Income-476.87K
Net Income-476.87K
EBITDA0.00
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -652.57K and capital expenditures 0.00, giving a free cash flow of -652.57K billion.
Operating Cash Flow-652.57K
Free Cash Flow-652.57K
Free Cash Flow per Share>-0.01
Dividends & Yields
Invex Therapeutics Ltd. pays an annual dividend of AU$0.186, resulting in a dividend yield of ―
Dividend Per ShareAU$0.186
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.72
52-Week Price Change31.43%
50-Day Moving Average0.11
200-Day Moving Average0.11
Relative Strength Index (RSI)9.55
Average Volume (3m)49.57K
Important Dates
Invex Therapeutics Ltd. upcoming earnings date is Aug 21, 2026, TBA (Not Confirmed).
Last Earnings DateFeb 12, 2026
Next Earnings DateAug 21, 2026
Ex-Dividend Date―
Financial Position
Invex Therapeutics Ltd. as a current ratio of 24.79, with Debt / Equity ratio of 0.00%
Current Ratio24.79
Quick Ratio24.79
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Invex Therapeutics Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Invex Therapeutics Ltd. EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -2.09.
EV to Sales5.94
EV to EBITDA0.00
EV to Free Cash Flow-2.09
EV to Operating Cash Flow-2.09
Balance Sheet
Invex Therapeutics Ltd. has AU$5.38M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$5.38M billion.
Cash & Marketable SecuritiesAU$5.38M
Total DebtAU$0.00
Net CashAU$5.38M
Net Cash Per ShareAU$0.07
Tangible Book Value Per ShareAU$0.07
Margins
Gross margin is 100.00%, with operating margin of -309.63%, and net profit margin of -208.16%.
Gross Margin100.00%
Operating Margin-309.63%
Pretax Margin-208.16%
Net Profit Margin-208.16%
EBITDA Margin0.00%
EBIT Margin-309.63%
Analyst Forecast
The average price target for Invex Therapeutics Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast71.10%